My watch list
my.bionity.com  
Login  

Endotis Pharma presents data on the neutralizable anticoagulant EP217609 in an extracorporeal circulation model

04-Jun-2010

Endotis Pharma presented that initial results on the neutralizable anticoagulant EP217609 in a canine model of extracorporeal circulation (ECC) at the French Society of Thoracic and Cardiovascular Surgery's 63th annual meeting in Tours, France.

Both EP217609 and its specific antidote avidin were well tolerated in this clinically relevant animal study. A single dose of EP217609 resulted in efficient, stable anticoagulation throughout the ECC procedure. Subsequent administration of avidin produced rapid, complete, irreversible neutralization and no rebound effect. There was no evidence of clotting in the extracorporeal circuits.

EP217609 is a first-in-class synthetic, parenteral anticoagulant which can be neutralized by a specific antidote avidin (EP5001). EP217609 has a dual mechanism of action which combines direct (free and clot-bound) thrombin inhibition and indirect factor Xa inhibition.

In April, Endotis announced that EP217609 and its specific antidote avidin had successfully completed their respective first-in-man Phase I clinical trials and that a study assessing the neutralization of EP217609 by avidin in healthy subjects will be initiated this summer.

Facts, background information, dossiers
More about Endotis Pharma
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE